Sodium-glucose Transport 2 Inhibitors (SGLT2i) in HFrEF Patients

Summary

The aim of this study is to assess the efficacy, safety and cardiovascular outcomes of Sodium-glucose transport protein 2 inhibitors (SGLT2i) therapy in patients with heart failure reduced ejection fraction ( HFrEF) with and without diabetes mellitus and is to evaluate short-term effect of these drugs using the cardiac biomarkers Neopterin.

Timeline

Start

2022-11-01

Primary completion

2024-12-01

Completion

2024-12-30

Drugs

Indications